PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Archives of pharmacal research

• Publication date

  2009-05-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12272-009-1511-8PMID 19471887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or oedema?

  2007cited by this paper
• Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

  2007cited by this paper
• Rodent Carcinogenicity Profile of the Antidiabetic Dual PPAR α and γ Agonist Muraglitazar

  2007cited by this paper
• Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.

  2007cited by this paper
• Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

  2007cited by this paper
• Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity

  2006cited by this paper
• Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.

  2006cited by this paper
• Benzoyl 2-methyl indoles as selective PPARγ modulators

  2005cited by this paper
• Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Selective PPARγ modulators with improved pharmacological profiles

  2005cited by this paper
• GI262570, a Peroxisome Proliferator-Activated Receptor γ Agonist, Changes Electrolytes and Water Reabsorption from the Distal Nephron in Rats

  2005cited by this paper
• Selective PPARgamma modulators with improved pharmacological profiles.

  2005cited by this paper
• Benzoyl 2-methyl indoles as selective PPARgamma modulators.

  2005cited by this paper
• Reduced baroreflex control of heart period after bed rest is normalized by acute plasma volume restoration.

  2004cited by this paper
• Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.

  2004cited by this paper
• Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.

  2004cited by this paper
• Peroxisome proliferator-activated receptor γ in diabetes and metabolism

  2004cited by this paper
• PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

  2002cited by this paper
• Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

  2001cited by this paper
• Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

  2000cited by this paper
• Diabetes complications: why is glucose potentially toxic?

  1996cited by this paper
• mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.

  1994cited by this paper
• Chronic effects of vasopressin on fluid volume distribution in conscious dogs.

  1986cited by this paper

• Cyanidin-3-rutinoside(C3R) attenuates free fatty acid-induced hepatic lipid accumulation in HepG2 cells

  2026cites this paper
• Macrophage fatty acid oxidation in atherosclerosis.

  2023cites this paper
• Tetrazoles as PPARγ ligands: A Structural and Computational Investigation

  2021cites this paper
• Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

  2020cites this paper
• DMSO_A_265399 3627..3635

  2020cites this paper
• To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations

  2020cites this paper
• PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation

  2017influential citation
• Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice.

  2016cites this paper
• Multitargeted bioactive ligands for PPARs discovered in the last decade

  2016cites this paper
• On the Metabolically Active Form of Metaglidasen: Improved Synthesis and Investigation of Its Peculiar Activity on Peroxisome Proliferator‐Activated Receptors and Skeletal Muscles

  2015cites this paper
• The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin.

  2015cites this paper
• PPARγ ligands and their therapeutic applications: a patent review (2008 – 2014)

  2015cites this paper
• Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models

  2012cites this paper
• Novel Transcriptome Profiling Analyses Demonstrate that Selective Peroxisome Proliferator-Activated Receptor γ (PPARγ) Modulators Display Attenuated and Selective Gene Regulatory Activity in Comparison with PPARγ Full Agonists

  2012cites this paper
• Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.

  2012cites this paper
• Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.

  2012cites this paper
• Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.

  2012cites this paper
• Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)

  2012cites this paper
• Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders

  2012cites this paper
• Novel Transcriptome Profiling Analyses Demonstrate that Selective PPAR γ Modulators Display Attenuated and Selective Gene Regulatory Activity in Comparison with PPAR γ Full Agonists

  2012cites this paper
• Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods.

  2011cites this paper
• Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, Cerco-A.

  2011cites this paper
• Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

  2010influential citation
• Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.

  2010cites this paper